A 61.2% increase in the number of samples (both urine and non-ABP blood samples) analyzed and reported into ADAMS: 149,758 in 2020 to 241,430 in 2021. It should be noted that the COVID-19 pandemic significantly impacted the number of samples collected in 2020.
An increase in the total number of samples analyzed and reported by nearly all WADA-accredited laboratories and WADA-approved laboratories into ADAMS in 2021 compared to 2020.
An increase in the total number and percentage of non-ABP blood samples analyzed: 7.3% (10,940 of 149,758 samples) in 2020 to 9.3% (22,398 Blood + DBS samples out of 241,430).
An increase of 36% in the number of ABP blood samples analyzed: 22,666 in 2020 to 30,821 in 2021.
A decrease in the total percentage of AAFs: 0.67% in 2020 (1,009 AAFs from 149,758 samples) to 0.65% (1,560 AAFs from 241,430 samples).
An increase in the total number of AAFs for growth hormone (GH): 1 in 2020 to 7 in 2021, including the first reported AAF for a GH biomarker.